AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Sources (6)
- AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports Reuters · 50d ago
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 50d ago
- AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidates Endpoints News · 50d ago
- AbbVie paying $10.9B to buy Waltham biotech NBC Boston · 50d ago
- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal Yahoo Finance · 50d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 50d ago broke it first
Related trends
World's largest sovereign wealth fund posts record $184 billion profit as it reveals SpaceX stake for the first time
Norway’s $2.3 trillion fund hits a record $184 billion profit, buoyed by Asian tech and a fresh $1.2 billion SpaceX stake.
The Trump administration claims oil is flowing normally again. There’s just one problem
US oil output steadies as the Trump administration touts a 15‑million‑bpd Gulf flow amid lingering Middle‑East shut‑ins
Why the historic U.S.-Japan intervention has failed to halt the yen’s slide
A joint U.S.–Japan yen rescue falters as the currency keeps sliding despite high‑level vows.
GM reaches up to $4.5 billion parts deal designed to avoid supply chain troubles
General Motors has established a financial safety net worth up to $4.5 billion to protect its production lines from sudden supply chain disruptions.
Toyota recalls 655K Camrys over display error that may deactivate turn signals and other indicators
Toyota initiates a major recall affecting hundreds of thousands of Camry sedans due to a digital display and software bug.
Why Nvidia Is Trying To Develop The World’s Best Open-Source AI Models
Nvidia has launched the Nemotron 3.5 Lightning open-source AI model while also working on larger Nemotron 4 models.